Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Newron Pharmaceuticals S.P.A. (NWRN) Eur0.20

Sell:7.00 CHF Buy:7.02 CHF Change: 1.20 CHF (20.62%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.00 CHF
Buy:7.02 CHF
Change: 1.20 CHF (20.62%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:7.00 CHF
Buy:7.02 CHF
Change: 1.20 CHF (20.62%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

Contact details

via Ludovico Ariosto 21
+39 (02) 6103461

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
103.86 million CHF
Shares in issue:
17.85 million
SIX Swiss Exchange
Swiss Franc
Swiss All Share Index

Key personnel

  • Ulrich Kostlin
    Chairman, Non-Executive Director
  • Stefan Weber
    Chief Executive Officer, Executive Director, Investor Relations Officer
  • Roberto Galli
    Vice President Finance
  • Dennis Dionne
    Vice President Commercial Affairs
  • Marco Caremi
    Executive Vice President Business Development
  • Ravi Anand
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.